More from MRK Q2 2026

1mo

LIPFENDRA approval as first oral PCSK9 inhibitor and access plan

FDA approval of LIPFENDRA was described as the first and only oral PCSK9 inhibitor for adults with hypercholesterolemia along with diet and exercise.
Management cited CORALreef Lipids results showing up to a 60% LDL cholesterol reduction when added to a statin.
Rob Davis emphasized label cleanliness and high physician/patient interest, with ordering beginning last week and pharmacy availability expected shortly.
On access timing, management said broad access is planned through pricing and launch setup but will take time to establish, expecting slower initial pace with long-term blockbuster potential.
Management discussed plans to put LIPFENDRA on TrumpRx based on the MFN agreement and said details on timing would follow as initial launch ramps.

1mo

Financial Performance Summary

Gross margin was 81.1%, down 1.1 percentage points, primarily due to higher inventory reserves.
KEYTRUDA family sales increased 4% to $8.4 billion, supported by uptake in earlier-stage cancers and continued demand in metastatic indications.
KEYTRUDA QLEX sales were $463 million, with physician/patient adoption increasing since the permanent J-code established in April.
Operating expenses increased to $12.6 billion and included a $5.7 billion charge for the acquisition of Terns Pharmaceuticals versus $200 million a year ago.
Reported a non-GAAP loss of $0.13 per share, including a one-time $2.31 per share charge tied to the Terns acquisition.
Total company revenue was $16.6 billion in Q2 2026, up 5% (or 4% excluding foreign exchange).
WELIREG sales were $588 million, up 75%, driven by continued demand in pulmonary arterial hypertension and progress with new U.S. patients and background therapy mixes.

1mo

Gross margin 81.1%

Gross margin fell primarily due to higher inventory reserves

Management reported gross margin declined 1.1 percentage points, primarily attributed to higher inventory reserves.

More from MRK Q2 2026

1mo

LIPFENDRA approval as first oral PCSK9 inhibitor and access plan

FDA approval of LIPFENDRA was described as the first and only oral PCSK9 inhibitor for adults with hypercholesterolemia along with diet and exercise.
Management cited CORALreef Lipids results showing up to a 60% LDL cholesterol reduction when added to a statin.
Rob Davis emphasized label cleanliness and high physician/patient interest, with ordering beginning last week and pharmacy availability expected shortly.
On access timing, management said broad access is planned through pricing and launch setup but will take time to establish, expecting slower initial pace with long-term blockbuster potential.
Management discussed plans to put LIPFENDRA on TrumpRx based on the MFN agreement and said details on timing would follow as initial launch ramps.

1mo

Financial Performance Summary

Gross margin was 81.1%, down 1.1 percentage points, primarily due to higher inventory reserves.
KEYTRUDA family sales increased 4% to $8.4 billion, supported by uptake in earlier-stage cancers and continued demand in metastatic indications.
KEYTRUDA QLEX sales were $463 million, with physician/patient adoption increasing since the permanent J-code established in April.
Operating expenses increased to $12.6 billion and included a $5.7 billion charge for the acquisition of Terns Pharmaceuticals versus $200 million a year ago.
Reported a non-GAAP loss of $0.13 per share, including a one-time $2.31 per share charge tied to the Terns acquisition.
Total company revenue was $16.6 billion in Q2 2026, up 5% (or 4% excluding foreign exchange).
WELIREG sales were $588 million, up 75%, driven by continued demand in pulmonary arterial hypertension and progress with new U.S. patients and background therapy mixes.

1mo

Gross margin 81.1%

Gross margin fell primarily due to higher inventory reserves

Management reported gross margin declined 1.1 percentage points, primarily attributed to higher inventory reserves.

Merck & Co., Inc. Earnings Quote from Rob Davis

More from MRK Q2 2026